Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain
  • Regulatory

VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain

Pharmaceutical Technology

VERTANICAL has received breakthrough therapy designation from the US FDA for VER-01, its investigational non-opioid treatment for chronic low back pain.

Pain & Anaesthesia

Read full story

pharminent May 19, 2026 (Last updated: May 21, 2026)

Pharmaceutical Technology

VERTANICAL has received breakthrough therapy designation from the US FDA for VER-01, its investigational non-opioid treatment for chronic low back pain.

Pain & Anaesthesia

Read full story

Post navigation

Previous: Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Next: Sanofi says drug for rare disease AATD tops standard care

Related Stories

  • Regulatory

Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa

pharminent August 20, 2026
  • Regulatory

Regeneron wins FDA approval to challenge Ipsen for rare bone disease market

pharminent August 20, 2026
  • Regulatory

FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy

pharminent August 20, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.